Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXY - Maxygen, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (220)	3/13/2007 7:25:39 PM
From: keokalani'nui	Respond to of 262

Although I had that up front in my own report I didn't attribute it and I can't find the source in my CC notes. It's possible I could have been projecting from an Oct 06 (reputable) brokerage report that said: "Under the terms of the agreement, Maxygen has retained full rights to the hemophilia indication and plans to start Phase 1 trials in 2007." Which was consistent with the way the company talked about the program, ie, all R had to do was solve manufacturing issues (an achievemnt they announced by CC), they had lots of cpd candidates (by CC), they thought they had a defensible IP mfg strategy (by CC), on track for IND etc, expect the milestones, etc, etc.